| Eyecare Of Livonia Pllc | |
|
13700 Middlebelt Rd, Livonia, MI 48150-2215 | |
| (734) 427-2944 | |
| (734) 853-3798 |
| Full Name | Eyecare Of Livonia Pllc |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 13700 Middlebelt Rd, Livonia, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578097259 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 4901003019 (Michigan) | Primary |
| Provider Name | Lisa M Barry |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1174670509 PECOS PAC ID: 4183512668 Enrollment ID: I20040306000235 |
News Archive
FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.
Patients admitted to the hospital with an acute coronary syndrome (ACS) are often treated with a catheter-based procedure known as percutaneous coronary intervention, or PCI.
Two University of Texas at Arlington professors known for their innovation in the world of chemistry have been named Fellows of the National Academy of Inventors.
More than 1.1 million Medicare patients could die over the next decade because they cannot afford to pay for their prescription medications, according to a new study released today by the West Health Policy Center, a nonprofit and nonpartisan policy research group and Xcenda, the research arm of the drug distributor AmerisourceBergen.
Janssen-Cilag Ltd today announced that NHS England will provide crucial funding for its once-daily, fixed-dose combination of darunavir and the pharmacoenhancer, cobicistat, called REZOLSTA.
› Verified 2 days ago
| Provider Name | William J Kiefiuk |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1821144916 PECOS PAC ID: 0749332252 Enrollment ID: I20090714000704 |
News Archive
FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.
Patients admitted to the hospital with an acute coronary syndrome (ACS) are often treated with a catheter-based procedure known as percutaneous coronary intervention, or PCI.
Two University of Texas at Arlington professors known for their innovation in the world of chemistry have been named Fellows of the National Academy of Inventors.
More than 1.1 million Medicare patients could die over the next decade because they cannot afford to pay for their prescription medications, according to a new study released today by the West Health Policy Center, a nonprofit and nonpartisan policy research group and Xcenda, the research arm of the drug distributor AmerisourceBergen.
Janssen-Cilag Ltd today announced that NHS England will provide crucial funding for its once-daily, fixed-dose combination of darunavir and the pharmacoenhancer, cobicistat, called REZOLSTA.
› Verified 2 days ago
| Provider Name | Jana Kadlec Drennan |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1053451922 PECOS PAC ID: 9133227788 Enrollment ID: I20160801000514 |
News Archive
FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.
Patients admitted to the hospital with an acute coronary syndrome (ACS) are often treated with a catheter-based procedure known as percutaneous coronary intervention, or PCI.
Two University of Texas at Arlington professors known for their innovation in the world of chemistry have been named Fellows of the National Academy of Inventors.
More than 1.1 million Medicare patients could die over the next decade because they cannot afford to pay for their prescription medications, according to a new study released today by the West Health Policy Center, a nonprofit and nonpartisan policy research group and Xcenda, the research arm of the drug distributor AmerisourceBergen.
Janssen-Cilag Ltd today announced that NHS England will provide crucial funding for its once-daily, fixed-dose combination of darunavir and the pharmacoenhancer, cobicistat, called REZOLSTA.
› Verified 2 days ago
| Provider Name | Mark S Hakim |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1598286569 PECOS PAC ID: 6204102437 Enrollment ID: I20180723001681 |
News Archive
FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.
Patients admitted to the hospital with an acute coronary syndrome (ACS) are often treated with a catheter-based procedure known as percutaneous coronary intervention, or PCI.
Two University of Texas at Arlington professors known for their innovation in the world of chemistry have been named Fellows of the National Academy of Inventors.
More than 1.1 million Medicare patients could die over the next decade because they cannot afford to pay for their prescription medications, according to a new study released today by the West Health Policy Center, a nonprofit and nonpartisan policy research group and Xcenda, the research arm of the drug distributor AmerisourceBergen.
Janssen-Cilag Ltd today announced that NHS England will provide crucial funding for its once-daily, fixed-dose combination of darunavir and the pharmacoenhancer, cobicistat, called REZOLSTA.
› Verified 2 days ago
| Provider Name | Rachel Elizabeth Toth |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1144848839 PECOS PAC ID: 0042635518 Enrollment ID: I20200730002122 |
News Archive
FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.
Patients admitted to the hospital with an acute coronary syndrome (ACS) are often treated with a catheter-based procedure known as percutaneous coronary intervention, or PCI.
Two University of Texas at Arlington professors known for their innovation in the world of chemistry have been named Fellows of the National Academy of Inventors.
More than 1.1 million Medicare patients could die over the next decade because they cannot afford to pay for their prescription medications, according to a new study released today by the West Health Policy Center, a nonprofit and nonpartisan policy research group and Xcenda, the research arm of the drug distributor AmerisourceBergen.
Janssen-Cilag Ltd today announced that NHS England will provide crucial funding for its once-daily, fixed-dose combination of darunavir and the pharmacoenhancer, cobicistat, called REZOLSTA.
› Verified 2 days ago
| Provider Name | Stephanie Krieg |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1881207389 PECOS PAC ID: 6002228285 Enrollment ID: I20201211000675 |
News Archive
FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.
Patients admitted to the hospital with an acute coronary syndrome (ACS) are often treated with a catheter-based procedure known as percutaneous coronary intervention, or PCI.
Two University of Texas at Arlington professors known for their innovation in the world of chemistry have been named Fellows of the National Academy of Inventors.
More than 1.1 million Medicare patients could die over the next decade because they cannot afford to pay for their prescription medications, according to a new study released today by the West Health Policy Center, a nonprofit and nonpartisan policy research group and Xcenda, the research arm of the drug distributor AmerisourceBergen.
Janssen-Cilag Ltd today announced that NHS England will provide crucial funding for its once-daily, fixed-dose combination of darunavir and the pharmacoenhancer, cobicistat, called REZOLSTA.
› Verified 2 days ago
| Provider Name | Marina J Garmo |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1942877691 PECOS PAC ID: 0042611402 Enrollment ID: I20210623002622 |
News Archive
FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.
Patients admitted to the hospital with an acute coronary syndrome (ACS) are often treated with a catheter-based procedure known as percutaneous coronary intervention, or PCI.
Two University of Texas at Arlington professors known for their innovation in the world of chemistry have been named Fellows of the National Academy of Inventors.
More than 1.1 million Medicare patients could die over the next decade because they cannot afford to pay for their prescription medications, according to a new study released today by the West Health Policy Center, a nonprofit and nonpartisan policy research group and Xcenda, the research arm of the drug distributor AmerisourceBergen.
Janssen-Cilag Ltd today announced that NHS England will provide crucial funding for its once-daily, fixed-dose combination of darunavir and the pharmacoenhancer, cobicistat, called REZOLSTA.
› Verified 2 days ago
| Provider Name | Erica J Kerney |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1376117630 PECOS PAC ID: 8729481825 Enrollment ID: I20210727003446 |
News Archive
FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.
Patients admitted to the hospital with an acute coronary syndrome (ACS) are often treated with a catheter-based procedure known as percutaneous coronary intervention, or PCI.
Two University of Texas at Arlington professors known for their innovation in the world of chemistry have been named Fellows of the National Academy of Inventors.
More than 1.1 million Medicare patients could die over the next decade because they cannot afford to pay for their prescription medications, according to a new study released today by the West Health Policy Center, a nonprofit and nonpartisan policy research group and Xcenda, the research arm of the drug distributor AmerisourceBergen.
Janssen-Cilag Ltd today announced that NHS England will provide crucial funding for its once-daily, fixed-dose combination of darunavir and the pharmacoenhancer, cobicistat, called REZOLSTA.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Eyecare Of Livonia Pllc 5016 Wavewood Dr, Commerce Township, MI 48382-1362 Ph: (249) 249-4793 | Eyecare Of Livonia Pllc 13700 Middlebelt Rd, Livonia, MI 48150-2215 Ph: (734) 427-2944 |
News Archive
FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.
Patients admitted to the hospital with an acute coronary syndrome (ACS) are often treated with a catheter-based procedure known as percutaneous coronary intervention, or PCI.
Two University of Texas at Arlington professors known for their innovation in the world of chemistry have been named Fellows of the National Academy of Inventors.
More than 1.1 million Medicare patients could die over the next decade because they cannot afford to pay for their prescription medications, according to a new study released today by the West Health Policy Center, a nonprofit and nonpartisan policy research group and Xcenda, the research arm of the drug distributor AmerisourceBergen.
Janssen-Cilag Ltd today announced that NHS England will provide crucial funding for its once-daily, fixed-dose combination of darunavir and the pharmacoenhancer, cobicistat, called REZOLSTA.
› Verified 2 days ago
Omar Mallah, OD Optometrist Medicare: Medicare Enrolled Practice Location: 29474 7 Mile Rd, Livonia, MI 48152 Phone: 248-615-2815 | |
Dr. James S Engstrom, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 13700 Middlebelt Rd, Livonia, MI 48150 Phone: 734-427-2944 | |
Marston Optometry, P.c. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 32037 Plymouth Rd, Livonia, MI 48150 Phone: 734-421-5454 Fax: 734-421-6133 | |
Mr. Gerald N Blaize, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 33012 7 Mile Rd, Livonia, MI 48152 Phone: 248-482-2020 Fax: 248-476-6441 | |
Svs Vision 06 Optometrist Medicare: Not Enrolled in Medicare Practice Location: 29691 7 Mile Rd, Livonia, MI 48152 Phone: 734-421-2844 Fax: 734-421-2878 | |
K & K Optical Inc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 28209 7 Mile Rd, Livonia, MI 48152 Phone: 248-777-2830 Fax: 248-777-9376 | |
Dr. Carol Lynn Marston-foucher, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 32037 Plymouth Rd, Livonia, MI 48150 Phone: 734-421-5454 Fax: 734-421-6133 |